Home
/
LISATA THERAPEUTICS, INC.
/
Financials
/
Quarterly
LISATA THERAPEUTICS, INC. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that LISATA THERAPEUTICS, INC. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2017
Mar 31, 2017
$7.92M
May 15, 2017
Q3
2016
Sep 30, 2016
$9.32M
Nov 7, 2016
Q2
2016
Jun 30, 2016
$8.30M
Aug 9, 2016
Q1
2017
Mar 31, 2016
$7.49M
May 15, 2017
Q3
2016
Sep 30, 2015
$5.89M
Nov 7, 2016
Q2
2016
Jun 30, 2015
$5.87M
Aug 9, 2016
Q1
2016
Mar 31, 2015
$3.17M
May 5, 2016
Q3
2015
Sep 30, 2014
$4.12M
Nov 5, 2015
Q2
2015
Jun 30, 2014
$4.49M
Aug 6, 2015
Q1
2015
Mar 31, 2014
$4.06M
May 6, 2015
Q3
2014
Sep 30, 2013
$3.71M
Oct 30, 2014
Q2
2014
Jun 30, 2013
$4.36M
Aug 7, 2014
Q1
2014
Mar 31, 2013
$2.52M
May 8, 2014
Q3
2013
Sep 30, 2012
$4.43M
Nov 7, 2013
Q2
2013
Jun 30, 2012
$3.37M
Aug 8, 2013
Q1
2013
Mar 31, 2012
$3.77M
May 9, 2013
Q3
2012
Sep 30, 2011
$2.18M
Nov 13, 2012
Q2
2012
Jun 30, 2011
$2.21M
Aug 14, 2012
Q1
2012
Mar 31, 2011
$19.59M
May 11, 2012
Q3
2011
Sep 30, 2010
$16.48M
Nov 10, 2011
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$0
Nov 6, 2025
Q2
2025
Jun 30, 2025
$70.0K
Aug 7, 2025
Q1
2025
Mar 31, 2025
$0
May 8, 2025
Q3
2025
Sep 30, 2024
$0
Nov 6, 2025
Q2
2025
Jun 30, 2024
$0
Aug 7, 2025
Q1
2025
Mar 31, 2024
$0
May 8, 2025
Q3
2024
Sep 30, 2023
$0
Nov 12, 2024
Q2
2024
Jun 30, 2023
$0
Aug 12, 2024
Q1
2024
Mar 31, 2023
$0
May 9, 2024
Q3
2023
Sep 30, 2022
$0
Nov 2, 2023
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($4.25M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($4.66M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($4.72M)
May 8, 2025
Q3
2025
Sep 30, 2024
($4.93M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($5.04M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($5.40M)
May 8, 2025
Q3
2024
Sep 30, 2023
($5.26M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($4.03M)
Aug 12, 2024
Q1
2024
Mar 31, 2023
($6.19M)
May 9, 2024
Q3
2023
Sep 30, 2022
($37.38M)
Nov 2, 2023
Q2
2023
Jun 30, 2022
($6.63M)
Aug 14, 2023
Q1
2023
Mar 31, 2022
($4.23M)
May 9, 2023
Q3
2022
Sep 30, 2021
($6.93M)
Nov 10, 2022
Q2
2022
Jun 30, 2021
($5.68M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($8.06M)
May 5, 2022
Q3
2021
Sep 30, 2020
($5.33M)
Nov 4, 2021
Q2
2021
Jun 30, 2020
$6.60M
Aug 5, 2021
Q1
2021
Mar 31, 2020
($3.99M)
May 6, 2021
Q3
2020
Sep 30, 2019
($4.90M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($5.14M)
Aug 13, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($4.41M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($4.87M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($5.85M)
May 8, 2025
Q3
2025
Sep 30, 2024
($5.34M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($5.52M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($6.60M)
May 8, 2025
Q3
2024
Sep 30, 2023
($5.96M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($6.88M)
Aug 12, 2024
Q1
2024
Mar 31, 2023
($6.84M)
May 9, 2024
Q3
2023
Sep 30, 2022
($37.72M)
Nov 2, 2023
Q2
2023
Jun 30, 2022
($6.72M)
Aug 14, 2023
Q1
2023
Mar 31, 2022
($6.62M)
May 9, 2023
Q3
2022
Sep 30, 2021
($6.97M)
Nov 10, 2022
Q2
2022
Jun 30, 2021
($7.15M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($8.09M)
May 5, 2022
Q3
2021
Sep 30, 2020
($5.35M)
Nov 4, 2021
Q2
2021
Jun 30, 2020
($4.29M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($4.06M)
May 6, 2021
Q3
2020
Sep 30, 2019
($5.07M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($5.35M)
Aug 13, 2020